SANTA BARBARA, Calif., Oct. 26, 2017 /PRNewswire/ -- Evolus, Inc. (www.Evolus.com) received confirmation from Health Canada that the New Drug Submission (NDS) for prabotulinumtoxinA, a 900 kilodalton (kDa) Botulinum toxin Type A, for the treatment of ...
more»